Rationale Hypersignaling of corticotropin releasing factor (CRF) has been implicated in stress disorders; however, many of its downstream mechanisms of action remain unclear. In vitro, CRF 1 receptor activation initiates multiple cell signaling cascades, including protein kinase A (PKA), protein kinase C (PKC), and mitogen-activated protein kinase kinase MEK1/2 signaling. It is unclear, however, which of these signaling cascades mediate CRF-induced behaviors during stress. Objectives We examined the role of PKA, PKC, and MEK1/2 signaling pathways in CRF-induced anxiety as measured by startle hyperreactivity. Methods Mice treated with intracerbroventricular (ICV) ovine CRF (oCRF) were pretreated with the PKA inhibitor Rp-cAMPS, PKC inhibitor bisindolylmaleimide (BIM), or MEK1/2 inhibitor PD98059 (ICV) and assessed for acoustic startle reactivity. Results The PKC inhibitor BIM significantly attenuated CRF-induced increases in startle. BIM was also able to block startle increases induced by oCRF when both compounds were infused directly into the bed nucleus of stria terminalis (BNST). PKA and MEK1/2 inhibition had no significant effects on CRF-induced changes in startle at the dose ranges tested. CRF-induced disruption of prepulse inhibition was not significantly reversed by any of the three pretreatments at the dose ranges tested. Conclusions PKC signaling is required for CRF-induced increases in startle, and this effect is mediated at least in part at the BNST. These findings suggest that PKC signaling cascades (1) may be important for the acute effects of CRF to induce startle hyperreactivity and (2) support further research of the role of PKC signaling in startle abnormalities relevant to disorders such as posttraumatic stress disorder.
Introduction
Corticotropin releasing factor (CRF) is rapidly released during emotional and physiological stress to initiate HPA secretion required for survival and coordinate behavioral and physiological coping to stressors. Most animal studies show anxiogenic effects of enhanced CRF neurotransmission in the central nervous system (dominantly via type 1 CRF receptor signaling; Takahashi 2001; Müller et al. 2003) ; however, it can also exert stress coping actions and longterm stress adaptation (via type 2 CRF receptor signaling; Bale et al. 2000) . The startle response is an acute defensive response and is increased during stress or threat in humans and animals Grillon et al. 1993) . In rodents, CRF treatment mimics stress effects on startle, and both CRF and stress-induced increases in startle can be blocked by CRF 1 receptor antagonist treatment or deletion of the CRF 1 receptor gene (Swerdlow et al. 1989; Risbrough et al. 2004 Risbrough et al. , 2009 Walker et al. 2009b) . Elevated CRF levels and acute stress exposure both reduce habituation and inhibition of startle in animals (Conti et al. 2002; Risbrough et al. 2003 Risbrough et al. , 2004 Bakshi et al. 2012) . In humans, exaggerated startle reactivity and abnormally high cerebrospinal fluid levels of CRF are reported in individuals with posttraumatic stress disorder (PTSD) (Morgan et al. 1995; Grillon et al. 1996; Bremner et al. 1997; Baker et al. 1999; Sautter et al. 2003 ; for review, see Risbrough and Stein 2006) . Therefore, it has been hypothesized that brain CRF hypersecretion may contribute to increased arousal and dysregulation of the startle response in PTSD. This hypothesis is supported by data showing that central CRF administration increases startle reaction and decreases prepulse inhibition (PPI) in several experimental paradigms, such as unconditioned startle and light-and fear-potentiated startle (Swerdlow et al. 1989; Risbrough et al. 2009; Walker et al. 2009b; Bijlsma et al. 2011) . Conversely, pharmacological antagonism of the CRF 1 receptor before or immediately after predator stress blocks the development of enduring startle hyperreactivity in mice (Adamec et al. 2010) , suggesting that CRF hypersignaling during and after stress triggers a cascade of molecular events contributing to the persistent effects of trauma on startle hyperreactivity. One of the remaining questions is to identify downstream signaling pathways mediating CRF receptor activation effects on acute defensive behaviors such as startle reaction.
CRF acts on the two cloned G-protein-coupled CRF receptor subtypes (CRF 1 and CRF 2 ) to generate signals via the second messenger protein kinases A (PKA) and C (PKC) pathways as well as the extracellular regulated kinasemitogen activated protein kinase (MEK-ERK/MAPK) cascade. To activate the PKA pathway, CRF receptors couple to Gsα, thereby stimulating adenylate cyclase generation of cAMP; cAMP then activates PKA which phosphorylates cellular targets, modulates gene transcription, and influences neuronal excitability (Dautzenberg et al. 2004; Hillhouse and Grammatopoulos 2006; Hauger et al. 2009 ). To activate the PKC pathway, CRF receptors couple to the Gq protein, stimulating phospholipase C activity and intracellular calcium mobilization, in turn, leading to phosphorylation of PKC which also can phosphorylate cytosolic proteins, modulate gene transcription, and influence cell excitability (Ungless et al. 2003; Hauger et al. 2003; Dautzenberg et al. 2004; Hillhouse and Grammatopoulos 2006; Gutknecht et al. 2009 ). Various cellular mechanisms regulate CRF receptor signaling via the MEK-ERK cascade which modulates intracellular and nuclear events including gene transcription and neuronal plasticity (Sweatt 2001; Punn et al. 2006; Hauger et al. 2009 ).
Involvement of the PKA pathway in startle reactivity is supported by evidence that cAMP increases startle response when administered into the spinal cord or the nucleus reticularis pontis (Boulis and Davis 1990; de Lima and Davis 1995) . Additionally, increased PKA activity results in disrupted PPI (Kelly et al. 2007) , and PKA mediates the startle hyperactivity phenotype in phosphodiesterase-4B-deficient mice (Siuciak et al. 2008) . The inhibition of PKC in the spinal cord, however, increases startle reactivity (Boulis and Davis 1990) . Although these data suggest that PKA and PKC play a role in the execution of startle response and sensorimotor gating, their role in startle hyperreactivity induced by stress, CRF, or threat stimuli is unknown. Activation of the MEK-ERK pathway is required for long-term potentiation in the amygdala and for Pavlovian fear conditioning and fearpotentiated startle (Schafe et al. 2000; Di Benedetto et al. 2009 ). Central CRF administration and stress also activate the MEK-ERK signaling in several neuronal circuits that modulate startle behavior including the bed nucleus of stria terminalis (BNST), amygdala, and hippocampus (Schafe et al. 2000; Di Benedetto et al. 2009; Todorovic et al. 2009 ), suggesting that the MEK-ERK signaling could also play a role in stress or CRF-induced startle hyperreactivity.
Here we tested the hypothesis that PKA, PKC, and/or MEK-ERK signaling mediate the effects of CRF on startle behaviors. To test this hypothesis, we examined the effects of pretreatment with PKA, PKC, and/or MEK inhibitors on CRF-induced increases in startle and reductions in PPI. We also examined if this mechanism was found directly in the BNST, a critical region for CRF receptor activation effects on startle behavior (Waddell et al. 2008; Walker et al. 2009a; Lee and Davis 1997) .
Methods

Subjects
Male C57BL/6 mice (2 months of age) from Jackson Laboratories (Bar Harbor, ME, USA) were used for these studies. All mice were housed in a temperature-and humidity-controlled room with a 12:12-h reverse light/dark cycle (lights off at 08:00) and food and water available ad libitum. All startle testing occurred between 10:00 and 18:00. All experiments were conducted in accordance with the statement revised and approved by the Society for Neuroscience in January 1995 and in accordance with "Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research" (National Research Council 2003) , as approved by the University of California, San Diego.
Surgery and histological verification
All mice were anesthetized using a ketamine/acepromazine cocktail (100/5 mg/kg, respectively). For the ICV cannulation surgery, a 23-gauge 7-mm unilateral guide cannulae was inserted into the lateral ventricle (flat skull; anteroposterior, −0.1 mm; mediolateral, ±1.1 mm; dorsoventral, −1.5 mm below dura). A 30-gauge 8-mm injector was used for ICV infusions (1 mm below the cannula tip). For the BNST surgeries, guide cannulae (23 gauge, 7 mm) were inserted bilaterally above the ventricles and 2.6 mm above the BNST, to minimize damage or blockage of the ventricles (flat skull; anteroposterior, −0.22 mm; mediolateral, ±0.8 mm; dorsoventral, −1.25 mm below dura). A beveled 30-gauge 9.6-mm injector was used to pass through the ventricle to pierce the BNST below (2.6 mm below the cannula tip). All cannulae were secured with one skull screw and dental cement (DenMat Corp., Santa Maria, CA, USA) and closed with a removable stylet. Mice recovered for at least 1 week prior to testing. Within 1 week after study completion, mice were anesthetized and 1.5 μl of dye was infused to check for cannulae placement. Mice were killed immediately, and as the brain was removed, the presence of dye in the fourth ventricle was noted. The presence of dye in the lateral and fourth ventricle was also noted by making a coronal cut along the guide tract. All brains were digitally scanned with the cut side on the slides. For BNST injections, brains were fixed with 4 % paraformaldehyde, cut to 25 μm sections and Nissl-stained. Mice with evidence of needle tracks outside the BNST were removed from the analysis. See Fig. 1 for schematic of injection sites of mice included in the analysis. Ten mice were removed from data analysis due to incorrect cannula placement. A total of three outliers in startle or prepulse inhibition measures (>3 standard deviations from the mean) were removed (one mouse from the 0.3-nmol bisindolylmaleimide (BIM)/ artificial cerebrospinal fluid (aCSF) group, peak startle=366; one mouse from the 1.0-nmol BIM/ovine CRF (oCRF) group, peak startle=831; one mouse from the 3.7-nmol Rp-cAMPS/oCRF group, PPI=−27). Drugs oCRF (Bachem, Torrance, CA, USA) was infused (0.24 nmol in 5 μl, ICV) 45 min before the test. Doses and timing were based on previous studies (Risbrough et al. 2003 (Risbrough et al. , 2004 Gresack and Risbrough 2011) . The PKC inhibitor BIM (Calbiochem, San Diego, CA, USA) was infused (0.01-3.0 nmol in 5 μl, ICV) 60 min before oCRF. Both oCRF and BIM were dissolved in aCSF vehicle. The PKA inhibitor RpcAMPS (Biolog Lifescience Institute, Bremen, Germany) was infused (30-200 nmol dissolved in sterile water, 5 μl, ICV) 60 min before oCRF. The MEK inhibitor PD98059 (Calbiochem, San Diego, CA, USA) was similarly infused (1.1-11 nmol in 2 μ, ICV) 60 min prior to oCRF. The vehicle for the MEK inhibitors was 30 % DMSO/water. Doses and time course for all inhibitors were based on observations from pilot experiments and previous reports (Bourtchouladze et al. 1998; Schafe et al. 1999 Schafe et al. , 2000 Lu et al. 2001; Sananbenesi et al. 2003; Selvamani et al. 2007 ). ICV infusions were by gravity after which the injector remained in place for 1 min before removal. In all studies except the oCRF dose response in the BNST (see below), a between-subject design was used.
For the dose response of oCRF in the BNST, oCRF (0.02 and 0.04 nmol in 0.25 μl/side) was infused directly into the BNST and testing was 60 min after injection (doses chosen based on Davis et al. 1997 in rats) . In this study, we used a crossover design with a 1-week washout between injections and counterbalancing for dose order. In the second BNST experiment, we used a between-subject design to reduce LGP globus pallidus, lateral part; aca anterior commissure; ic internal capsule; st stria terminalis; ox optic chiasm; f fornix confounds of damage to the ventricle by repeated injections. BIM (0.06 nmol in 0.25 μl/side) was infused directly into the BNST 60 min prior to oCRF (0.02 nmol in 0.25 μl/side) which was infused 45 min prior to the test. BNST infusions were at a 0.1-μl/min rate after which injectors remained in place for 3 min before removal. This 3-min period was to ensure adequate diffusion into tissue and to minimize fluid loss to the ventricles upon injector removal.
Apparatus
Startle and PPI testing were performed in ventilated, soundattenuating commercial startle chambers (39×38×58 cm, SR-LAB System, San Diego Instruments, San Diego, CA, USA) consisting of a nonrestrictive Plexiglas cylinder (5 cm in diameter) into which the animal was placed. The cylinder was attached to a Plexiglas platform. Movements by the mouse were detected by a piezoelectric accelerometer attached below the platform. The mouse's movements were then digitized and stored by an interface and computer assembly. A loudspeaker provided continuous broadband 65-dB background noise and all acoustic stimuli (see below). Beginning at startle stimulus onset, 65 consecutive 1-ms readings were recorded to obtain the average amplitude of the mouse's startle response. The chamber house light was off during all testing. Apparatus was calibrated and stimuli were verified as previously described (Risbrough and Geyer 2005) .
Behavioral testing
The entire experimental session consisted of a 2-min acclimation period, followed by a block of four 120-dB pulse trials (block 1) and a variable prepulse intensity block of trials (block 2). The variable prepulse intensity block consisted of 10 startle pulse-alone trials (each at 120 dB, 40 ms duration) and 30 prepulse + pulse trials. The prepulse + pulse trials were evenly divided among the following trial types (10 each): a 69-, 73-, or 77-dB prepulse preceding a 120-dB pulse stimulus. All prepulses were 20 ms in duration and all startle pulses were 40 ms. The interstimulus interval between prepulse and pulse onset was 100 ms. The average intertrial interval for all trial types throughout the session was 15 s (range of 6-21 s). All trial types within the prepulse intensity block were presented in a pseudorandom order. The startle testing session for the within-subject BNST dose response study was slightly different. It also began with four 120-dB trials (block 1). Unlike the studies above, block 1 was followed by a block of different pulse intensities to examine if CRF effects in the BNST were dependent on pulse intensity (eight each of 90, 105, and 120 dB, 40 ms in duration). CRF showed a similar pattern of drug action in both block 1 and across the different pulse intensity block; thus, for consistency to compare to the ICV studies, we will show block 1 data. The next block was the same prepulse trial block as described for the other studies ("block 2").
Data analysis
The average startle magnitude over the record window (65 ms) was used for all data analysis. As in previous studies, CRF has the strongest effect on startle in the initial phase of the session (block 1) before prepulse trials are introduced (Gresack and Risbrough 2011) , and this block was used for all startle analyses. To test the effects of the inhibitors on CRF-induced increases in startle, a two-way analysis of variance (ANOVA) was used with BIM, PD98059, or Rp-cAMPs pretreatment and oCRF treatment as the between-subject factors. For PPI assessment, percentage of PPI was first calculated using the formula: 100−((average startle of the prepulse+pulse trials/average startle in the pulse alone trial)×100). A three-way ANOVA, with BIM, PD98059, or Rp-cAMPs pretreatment and oCRF treatment as the between-subject factors and prepulse intensity as the within-subject factor, was used for %PPI statistical analysis. Post hoc analyses followed significant main or interaction effects as appropriate using Tukey's or Dunnett's post hoc tests.
Results
Contribution of PKC to CRF-induced alterations in startle
To investigate potential regulation of startle behavior by Gq-coupled CRF receptor signaling, we pretreated mice with BIM, which is reported to have the best selectivity for competitively inhibiting the ATP binding site of protein kinase C (especially the α-, β-, δ-, ε-, and z-isoforms of PKC) with less effects on other kinases . oCRF increased startle magnitude; however, this effect was dependent upon treatment with the PKC inhibitor BIM (CRF × BIM interaction: F(5, 83)=3.00, p<0.05). Both the 0.3-and 3-nmol doses of BIM significantly attenuated oCRF-induced increases in startle ( Fig. 2; p <0 .01 vs. Veh/oCRF-treated group, Dunnett's post hoc test). BIM treatment had no significant effect on startle when given alone (Fig. 2) .
To determine if the BNST is the neural substrate for CRF effects on startle, we first examined the effects of oCRF infusions in the BNST in mice. Using a within-subject design, we found that oCRF induced significant increases in startle reactivity at the 0.04-nmol dose (Fig. 3 ) (p<0.05 simple comparison following a main effect of dose: F(2, 22)=3.78, p<0.05). In the block presenting different pulse intensities (90, 105, 120 dB), oCRF effects were most predominant at the 120-dB trials (CRF × intensity: F(4, 44)=2.82, p<0.05; data not shown). oCRF infused into the BNST showed a trend to reduce prepulse inhibition (main effect of oCRF: F(2, 22)= 2.44, p=0.11; data not shown).
To determine effects of BIM on oCRF-induced alteration in startle, we chose the 0.02-and the 0.06-nmol dose of oCRF and BIM, respectively, which is 10 and five times lower than the effective dose using the ICV route ( Fig. 2 ; Risbrough et al. 2003 Risbrough et al. , 2004 . oCRFinduced increases in startle magnitude were reversed by pretreatment with BIM into the BNST (Fig. 3 ; oCRF × BIM: F(1, 31)=5.64, p<0.05). Tukey's post hoc analyses indicated that startle magnitude in the oCRF/Veh group was significantly greater than all other groups (ps<0.05).
ICV infusions of oCRF also decreased %PPI but this effect was not significantly altered by pretreatment with BIM ( Fig. 4 , left; main effect of CRF: F(1, 83)=10.78, p< 0.01; oCRF × BIM: F(5, 83)=1.79, p =0.12). When infused into the BNST, oCRF-induced decreases in PPI were not significantly affected by BIM pretreatment ( Fig. 4 ; main effect of oCRF: F(1, 31) = 4.41, p < 0.05; oCRF × BIM: F(1, 31)<1, p=0.44).
Contribution of PKA to CRF-induced alterations in startle
Here we determined if pretreatment with the highly selective, potent PKA inhibitor Rp-cAMPS, which has no effect on Gq-coupled CRF receptor signaling (Dautzenberg et al. 2004) , would alter startle responses to oCRF. oCRF produced similar increases in startle and reductions in PPI across both vehicle and Rp-cAMPS-pretreated mice (Table 1 ; main effect of CRF-startle: F(1, 102)=16.25, p<0.001; PPI: F(1, 102)=4.59, p<0.05; no significant interactions with Rp-cAMPS-startle and PPI: F(3, 102)<1, p>0.6). Rp-cAMPS pretreatment alone had no significant main effects on startle or PPI.
Contribution of MEK1/2-ERK to CRF-induced alterations in startle
Finally, we examined the role of CRF receptor signaling via the MEK1/2-ERK cascade in CRF-induced startle behavior. oCRF increased startle magnitude and reduced PPI independently of MEK1/2 inhibitor PD98059 treatment (Table 1 ; main effect of CRF-startle: F(1, 68)=42.88, p<0.001; PPI: F(1, 68)=19.18, p<0.001; no significant interactions with PD98059-startle: F(3, 68)=2.1, p=0.11; PPI: F(3, 68)<1, p=0.4). PD98059 treatment alone had no significant main effects on startle or PPI.
Discussion
Here we showed that ICV administration of oCRF induced a marked increase in startle magnitude which was attenuated by the PKC inhibitor BIM. ICV oCRF-induced startle hyperreactivity was reproduced by targeted administration of oCRF into the BNST, an effect that also could be attenuated by intra-BNST pretreatment with BIM. BIM treatment alone had no effect on startle magnitude, suggesting that BIM's effects were specific to blocking CRF receptor-induced PKC signaling. In contrast, inhibition of PKA and MEK1/2-ERK pathways by ICV injection of selective inhibitors did not significantly affect CRF-induced increases in startle. Prepulse inhibition was consistently decreased by oCRF treatment, but none of the inhibitors were able to significantly attenuate this effect at the dose ranges tested. We have previously established an important role for brain CRF 1 receptor hypersignaling in the marked increase in startle and decrease in PPI by demonstrating that pretreatment with a selective CRF 1 receptor antagonist or targeting deletion of the CRF 1 receptor gene can block CRF effects on startle behavior (Risbrough et al. 2003 (Risbrough et al. , 2004 ). The present findings broaden our knowledge of the downstream mechanisms of CRF receptor effects on startle behavior, indicating a central role of CRF receptor signaling via the PKC pathway in CRF-induced startle hyperreactivity but not in PPI deficits. These findings extend previous findings in rats , that the BNST is critically involved in CRFinduced hyperreactivity, by showing that CRF receptor PKC signaling in the BNST can mediate CRF effects on startle. CRF infusions into the BNST also reduce PPI, suggesting that CRFinduced activation in this region is also sufficient to induce PPI deficits. Neither ICV nor BNST BIM pretreatment significantly reversed CRF-induced PPI deficits. However, there did appear to be a nonsignificant increase in PPI in BIM/CRFtreated groups compared to VEH/CRF-treated groups, while the groups treated with BIM alone showed slightly reduced PPI. Thus, PKC inhibition may play a weak role in PPI with differential consequences dependent upon CRF tone; however, the present studies were not powered to detect this potentially weaker effect size.
The PKC pathway is involved in several behavioral effects of CRF and stress. CRF facilitation of contextual fear conditioning and long-term potentiation in the hippocampus is blocked by pretreatment with the PKC inhibitor BIM (Blank et al. 2002 (Blank et al. , 2003 . PKCγ-and PKCε-deficient mice show decreased anxiety in avoidance paradigms and reduced CRF in the amygdala (Bowers et al. 2000; Lesscher et al. 2008) . Although the causal relationship between CRF and PKC activity is not clear in the latter study, the findings do support a potential coupling between the CRF and PKC pathways. PKC activation is also required for acquisition of other learned avoidance responses, such as taste aversion (Yasoshima and Yamamoto 1997) , inhibitory avoidance (Walker and Gold 1994) , or in stressful spatial memory tasks (Wehner et al. 1990 ). Blockade of the constitutively active isoform of PKC, PKMζ, reduces fear-potentiated startle (Parsons and Davis 2011) or predator scent-induced startle hyperreactivity (Cohen et al. 2010) . These data support the role of different PKC isoforms in defensive responses, anxiety, and stressrelated learning and conditioning paradigms. Here, we showed that the PKC pathway mediates the effect of CRF on defensive startle, suggesting that PKC plays a role in stress-induced Startle  aCSF  80±20  144±23  121±15  159±30  212±30  209±18  185±18  221±56  oCRF   a   396±84  306±83  364±51  271±26  331±70  377±65  294±54  355±40  %PPI  aCSF  64±7  58±3  49±7  63±5  49±4  40±3  35±7  42±6  oCRF   a   39±5  39±7  43±8  44±5  38±6  32±5  34±4  31±4 startle reactivity and supports the importance of this CRF receptor signaling pathway in stress responses. The downstream events that mediate CRF-PKC signaling effects on startle are unknown; however, there are several neurotransmitter systems and neural substrate candidates. For instance, CRF-induced PKC activation was shown to increase serotonin-enhanced GABA release in the prefrontal cortex (Tan et al. 2004) , increase field potential amplitudes in the basolateral amygdala (Ugolini et al. 2008) , facilitate LTP and GABA release in the central amygdala (Pollandt et al. 2006; Bajo et al. 2008 ), induce NMDA current depression in hippocampal neurons (Sheng et al. 2008) , and increase excitability and firing rates of dopaminergic neurons of the ventral tegmental area (Ungless et al. 2003; Wanat et al. 2008) . The altered excitability of these regions may contribute to CRFinduced startle hyperreactivity as these region are known to modulate startle Walker et al. 2009a ). For instance, increased dopamine transmission has been shown to increase startle responses (Davis and Aghajanian 1976; Davis 1980; Davis et al. 1986 ) and dopamine D1 receptor activation mediates CRF effects on startle in rats (Meloni et al. 2006) . However, in mice, CRF-induced startle is unaffected by the genetic disruption and pharmacological blockade of D1 or D2 receptors, suggesting species differences in the signaling transduction pathways mediating CRF effects on startle (Vinkers et al. 2007 ). In mice, we have found that noradrenergic transmission via α1 receptor activation plays a permissive role in CRF-induced startle hyperreactivity (Gresack and Risbrough 2011) . Agonist-activated α1 receptors couple to Gq and can play a role in BNST-mediated anxiety behaviors via alteration in BNST neuronal excitability (Cecchi et al. 2002; McElligott et al. 2010) . Accordingly, BIM-induced inhibition of PKC pathways in the BNST may be disrupting NE signaling required for CRF effects on startle. Thus, it is possible that disruption of PKC is blocking CRF 1 activation effects or possible downstream α1 activation effects on startle.
Based on our present findings, CRF-induced startle hyperreactivity is linked to the PKC signaling cascade in the BNST, a key regulator of CRF-induced startle and its potentiation by stressful stimuli Koob 1999; Waddell et al. 2008; Walker et al. 2009a; Sink et al. 2013) . These findings in mice are in line with the known mediation of the BNST in CRF effects on startle in rats . The fact that both the BIM (0.06 nmol) and oCRF (0.02 nmol) doses that were effective in the BNST are lower than the doses that are ineffective when given ICV suggests that the effects of BIM to block oCRF-induced increases in startle are unlikely to be due to diffusion into the ventricles (highest ineffective ICV dose of BIM 0.1 nmol; Fig. 2 ; highest ineffective ICV dose of oCRF 0.06 nmol; Gresack and Risbrough 2011) . Although it is possible that CRF/BIM diffused to neighboring regions surrounding the BNST, the BNST either has (1) much higher CRF receptor expression and peptide levels compared to immediately surrounding nuclei (preoptic area, substantia innominata) or (2) CRF receptor activation in neighboring nuclei (globus pallidus) is associated with anxiolytic effects, opposite to what we see in the present studies (Van Pett et al. 2000; Sztainberg et al. 2011) . Additionally, the BNST controls other stress-related behaviors, such as inhibitory avoidance, social and nonsocial anxiety, and defensive behavior (Liang et al. 2001; Cooper and Huhman 2005; Sahuque et al. 2006; Lee et al. 2008) . Confirming the role of the BNST in stress responses, we showed that acute CRF receptor activation in the BNST induces startle hyperreactivity which is mediated (at least partly) by PKC pathway activation. Interestingly, unlike acute applications of CRF or acute stress induction, chronic CRF overexpression in the BNST does not affect startle reactivity (Regev et al. 2011; Sink et al. 2013) . Chronic CRF overexpression may result in (1) differential receptor desensitization, internalization, and downregulation; (2) shift receptor (CRF 1 or CRF 2 ) expression and activity ratios; or (3) induce other compensatory changes resulting in an altered behavioral outcome such that startle behavior is no longer affected (Price et al. 2002; Greetfeld et al. 2009; Waselus et al. 2009 ). CRF modulates GABAergic and glutamatergic transmission in the BNST, thus determining BNST excitability to different threatening stimuli (Kash and Winder 2006; Nobis et al. 2011; Oberlander and Henderson 2012) . Hence, long-term CRF overexpression may significantly alter the neuronal excitability of this region.
In contrast to PKC blockade, the PKA inhibitor RpcAMPS did not block the effect of CRF on startle and PPI at any doses used in this study. It is possible that higher doses of Rp-cAMPS might be more effective; however, in pilot studies, we found doses higher than 200 nmol were toxic, precluding their use. Another possible reason Rp-cAMPS was ineffective might be the treatment window used in the present studies (1.75 h before testing). However, it has been previously reported that PKA inhibition up to 3 h before testing blocks memory formation (Bourtchouladze et al. 1998) , suggesting that Rp-cAMPS has long-lasting effects. These negative findings are in contrast to cAMP, adenylate cyclase activators, or phosphodiesterase inhibitor treatments which increase startle if administered intrathecally or into the nucleus reticularis pontis, a central regulator of the startle response (Kehne et al. 1986; Boulis and Davis 1990; de Lima and Davis 1995) . However, none of these treatments alter startle when administrated into the lateral ventricles (Kehne et al. 1986; Boulis and Davis 1990; de Lima and Davis 1995) . Taken together with the present studies, PKA signaling may play a significant role in the execution of the startle response at the startle circuit but play less of a role in forebrain regions that modulate startle. This explanation is based on the assumption that ICV-administered treatments have more access to forebrain regions compared to brain stem and spinal cord. Similar to PKA inhibition, MEK1/2 inhibition had no significant effects on startle plasticity either alone or in conjunction with CRF treatment. Pilot studies using an alternative MEK1/2 inhibitor, U0126 (3 μg ICV, data not shown) also showed no effects on CRF-induced increases in startle or reductions in PPI. The MEK-ERK/MAPK pathway induces long-term behavioral effects by regulating gene transcription and neuronal plasticity, processes that occur over longer time periods than examined in our study (Sweatt 2001; Punn et al. 2006; Hauger et al. 2009 ). Therefore, a plausible interpretation of the lack of MEK1/2 inhibitor efficacy on startle reactivity is the short-term nature of our paradigm. CRF 1 receptors could activate the MEK-ERK pathway within 1 h, but protein translation and subsequent steps may require additional time. Supporting this interpretation, CRF-induced MEK-ERK pathway activation was able to increase the stress-induced enhancement of fear conditioning 24 h after stress (Radulovic et al. 1999; Sananbenesi et al. 2003) . In accordance, Schafe et al. (1999) showed that the inhibition of MAPK (and PKA) reduced contextual and auditory fear memories on a long-term (24 h) but left short-term (1 h) fear memory intact. Similarly, MEK inhibition immediately post training blocks recall of inhibitory avoidance 24 h later (Walz et al. 2000) . These data support the importance of de novo protein synthesis in the mediation of the MEK-ERK pathway effects on behavior. However, the blockade of the MEK-ERK pathway reduces depressive symptoms in the forced swim and tail suspension test in a 6-30-min time frame (Todorovic et al. 2009) , showing that this pathway is also capable of having short-term effects on stress-related behaviors. Based on this later finding, treatment time course is less likely a factor in the present negative results.
PTSD subjects exhibit increased fear learning and startle hyperreactivity (Grillon and Baas 2003; Grillon et al. 2009; Jovanovic et al. 2009; Glover et al. 2011) as well as elevated CRF levels in cerebrospinal fluid (Bremner et al. 1997; Baker et al. 1999; Sautter et al. 2003 ). Thus, it is possible that CRF hypersignaling plays a role in PTSD risk or symptoms (Steckler and Risbrough 2012) . CRF receptor activation enhances fear learning and anxiety via a PKC mechanism (Blank et al. 2002 (Blank et al. , 2003 Walker et al. 2009a) , in addition to the present findings that PKC signaling pathway mediates CRFinduced startle hyperreactivity. Interestingly, PKC signaling can mediate apical dendritic spine loss in hippocampal pyramidal neurons during chronic stress, while PKC inhibition reverses this stress effect (Hains et al. 2009 ). These data support the CRF-coupled PKC pathway as a target for future PTSD pharmacotherapies. Initial negative results with CRF 1 antagonists in depression and anxiety clinical trials have shifted CRF 1 drug development towards seeking alternative mechanisms, such as utilizing biased agonism or signal transduction selectivity (Zorrilla and Koob 2010; Hauger et al. 2012) . In accordance, there is growing body of evidence for the signal transduction selective nature of existing CRF 1 antagonists, showing their selectivity on Gq, Gi, or Gs proteins or their competitive and noncompetitive actions on different G protein subtypes (Berger et al. 2006; Beyermann et al. 2007; Zorrilla and Koob 2010) . This specificity could be utilized to develop drugs with more specific actions and improved side effect profile in the future. There are several different PKC isoforms that show specific distributions in the brain and at the subcellular level, e.g., location at pre-and postsynaptic compartments (Casabona 1997) , with most isoforms mediating stress-induced neurobiological and behavioral alterations in some form (see above). Thus, there is a need for further studies to clarify the functional role of PKC isoforms underlying stress and CRF-induced behavioral and neurobiological alterations, e.g., following traumatic experiences.
